Clinical Trial

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

Name: Study of Epcoritamab as a Consolidation Therapy in CLL/SLL — clinical trial record (NCT07108998)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a phase 2 study of Epcoritamab as a consolidation therapy for 2nd generation BTKi +/- Obinutuzumab in CLL/SLL patients or patients with variants of this.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-07-30.

Status change: Not Yet Recruiting → Recruiting 2026-01-02

Trial Details

NCT Number	NCT07108998
Lead Sponsor	Zulfa Omer Collaborators: Genmab
Conditions	CLL/SLL, CLL, SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma Variant, Chronic Lymphocytic Leukemia Variants
Enrollment	22 participants
Start Date	2025-08-22
Primary Completion	2027-07-01 (estimated)
Study Completion	2029-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-06